Praxsyn Announces Progress in Filing of Form 10-Q

        Print
| Source: Praxsyn Corporation

IRVINE, Calif., June 23, 2014 (GLOBE NEWSWIRE) -- Praxsyn Corporation (OTCQB:PAWS), a medication and service provider for medical practitioners, announced that it is making progress in filing its Form 10-Q for the quarter ended March 31, 2014.

"The work on the first quarter 10-Q continues and is meeting our internal completion deadlines," said Dan O'Brien, CFO, Praxsyn Corporation. "Our continued work requires the accounting team to conduct detailed research and confirm many historical facts and figures for several entities' most important accounts throughout the years 2012 and 2013, as well as the first quarter of 2014, which will then be submitted to our auditor. Based upon our ability to continue to complete this work and assuming continued progress at a similar rate, we hope to have all material information required for the 10-Q filing to our auditor by June 27, 2014."

As previously disclosed, the Company has not yet completed its financial statements for the quarter ended March 31, 2014 due to the increased workload from the complex accounting related to its recent reverse merger.

Praxsyn is headquartered in Southern California at 18011 Sky Park Circle, Suite N, Irvine, CA 92614, and can be contacted directly at (949) 777-6112.

About Praxsyn

At Praxsyn, we work to realize the vision of medical professionals to improve the lives of patients. Mesa Pharmacy, our wholly owned subsidiary, provides doctors with an alternative to oral pain medications. Mesa focuses on providing custom compounded non-narcotic, transdermal topical pain medications that are marketed to industrial health physicians and medical clinics. Mesa has developed a series of topical creams, in different strengths, that provide the pain relief doctors seek. Additional company information can be found at www.praxsyn.com.


Forward-Looking Statements

Certain statements made in this press release are forward-looking in nature (within the meaning of the Private Securities Litigation Reform Act of 1995) and, accordingly, are subject to risks and uncertainties. The actual results may differ materially from those described or contemplated and consequently, you should not rely on these forward-looking statements as predictions of future events. Certain of these risks and uncertainties are discussed in the reports we filed with the SEC.

Media/Investor Contact:

949-777-6112 ext 101